drugset / Trial / NCT07608796

JAK Signaling in Depression and Cognition in Male Football Players

NCT07608796

Phase 2 Not yet recruiting 30 enrolled Emory University
NaSingle-groupOpen-labelBasic science

Summary

This study is being done to learn more about the role of inflammation in depressive and cognitive symptoms in patients with depression who have played at least 10 years of organized football. This will be evaluated using a medication called baricitinib that blocks one aspect of inflammation.

Timeline

Start
2026-06
Primary completion
2027-10
Completion
2027-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Baricitinib Small molecule 2 mg Oral
Subject Baricitinib Small molecule 4 mg Oral